AZD1222 for COVID-19
This study is evaluating whether a drug called AZD1222 can prevent COVID-19.
See full descriptionAbout the trial for COVID-19
Treatment Groups
This trial involves 2 different treatments. AZD1222 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether AZD1222 will improve 7 primary outcomes and 24 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 7 days post each dose of study intervention..
Patient Q & A Section
What are common treatments for covid-19?
Many people affected by the coronavirus disease have access to non-pharmaceutical supportive interventions. These interventions include home treatment and self-care (e.g., handwashing), which can be improved by the provision of adequate supplies.
Can covid-19 be cured?
There are no known infectious agents that have been shown to cause clinical recovery. There is currently no evidence of a cure to the coronavirus disease 2019 (COVID-19). The case-fatality rate (CFR) has varied widely, and so far, in terms of the number of deaths, and the range has ranged from roughly 5% to around 43%. The most recent analysis predicts up to 60% fatalities in a developed country with a low-intensity, community spread pattern of transmission similar to that in European countries (i.e., where the transmission has been comparatively less severe).
How many people get covid-19 a year in the United States?
The number of new cases of COVID-19 per year estimated by the CDC as of 5 June 2020 is 6.1 cases per 100 000 persons of age (5.0 new cases per 100 000 persons of age, 95% confidence interval: 4.3 to 7.6; maximum likelihood estimate: 6.5 new cases per 100 000 persons of age, 95% lower limit: 3.2). About 2.5% (1.4% to 3.6%) of hospitalized patients and 2.3% (1.4% to 3.9%) of persons who died in those health care facilities had confirmed or probable COVID-19 infections.
What causes covid-19?
Age, sex, and race may be risk factors for severe and/or fatal outcomes of infected citizens in the United States. Preventative measures, such as limiting in-person social contacts with confirmed or suspected hospitalized cases, are recommended. Future studies on the clinical presentations are required to determine their impact on public health management and healthcare resource utilization.
What are the signs of covid-19?
There are several signs associated with the virus. Those include fever, cough, increased muscle and joint pains. Many people will also develop shortness of breath and a cough which is often dry or sticky in consistency.\n
What is covid-19?
The current report shows the impact of the outbreak on healthcare in the emergency department and the challenges faced when trying to mitigate the spread of the new coronavirus in an ever-changing clinical setting.
What are the common side effects of azd1222?
Overall, this study demonstrates that patients treated with AZD1222 at 20 mg/m2 experienced the highest rates of headache, dizziness, nausea, fatigue, constipation, decreased appetite and abdominal discomfort. As patients treated at higher doses of AZD1222 experienced an increase in dose-related hypersensitivity reactions and the highest rates of mild leukopenia, clinicians should consider administering AZD1222 at low doses at first and monitoring patients more often during the course of AZD1222 drug therapy.
Does azd1222 improve quality of life for those with covid-19?
Azd1222 for people with covid-19 and moderate-to-severe symptoms was well tolerated, had clinically meaningful effect on several domains of QoL, showed a rapid onset of treatment effects, and was well tolerated in a study with a small sample size. This proof-of-principle study demonstrates support for further investigation of AZD1222 in clinical populations. The clinical trial protocol for the study is available here: http://clinicaltrials.gov/ct2/show/NCT03074949.
Have there been other clinical trials involving azd1222?
[A Phase I/II clinical study of the immunoncologic drug azd1222 has been completed at our institution and has confirmed the preliminary safety profile seen in animal studies. Further investigation of this agent in the treatment of inflammatory conditions associated with a significant and progressive impairment of immune function is planned.
Have there been any new discoveries for treating covid-19?
There are also great advances for treating covid-19 by using lopinavir/ritonavir or chloroquine and/or azithromycin in addition to anti-viral drugs. We need a lot more research in this area. There are many unknown aspects for covid-19.
Has azd1222 proven to be more effective than a placebo?
In a recent study, findings confirm that it is safe to administer azd1222. The study suggests that azd1222 offers significant protection against moderate and severe pneumonia caused by SARS-CoV-2. In a recent study, findings is significant because there are no other vaccines that are ready for public use, and treatment options remain limited. The study also supports a potential role for SARS-CoV-2 vaccine development since it can provide significant protection in the event of a public health emergency.
Who should consider clinical trials for covid-19?
There is a high likelihood of a clinical trial being conducted as a response to the current outbreak of COVID-19; however, for both ethical and societal reasons, there is also a need to promote awareness of the potential benefits and harms of participating in such trials.